EBNA1BP2

Probable rRNA-processing protein EBP2 · Q99848 · EBNA1BP2 on Sugi Atlas →

0 patent compounds predicted against EBNA1BP2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to EBNA1BP2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mature B-Cell Lymphoma And Leukemia Study III PHASE2/PHASE3ACTIVE_NOT_RECRUITING
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma PHASE3ACTIVE_NOT_RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia PHASE2RECRUITING
A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE2UNKNOWN
Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours PHASE2UNKNOWN
A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes PHASE2COMPLETED
A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma PHASE2COMPLETED
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE2NOT_YET_RECRUITING
Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors PHASE1ACTIVE_NOT_RECRUITING
Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL) PHASE1WITHDRAWN
Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer PHASE1COMPLETED
Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer PHASE1COMPLETED
A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy nanCOMPLETED
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study nanUNKNOWN
Molecular Mechanism of Nasopharyngeal Carcinoma nanUNKNOWN
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia nanUNKNOWN
Cluster Randomized Controlled Screening Trial for NPC nanUNKNOWN
Comparison of Technics for Determination of Epstein-Barr Virus Serological Diagnosis nanCOMPLETED
Esophageal String Test in Eosinophilic Esophagitis nanACTIVE_NOT_RECRUITING
Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations nanCOMPLETED
Comparison Between Clinical and MRI Multiple Sclerosis Activity and Expression of Human Endogenous Retrovirus Type W and Herpesvirus nanUNKNOWN
Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NCP Susceptibility Gene(s) nanCOMPLETED
Genetic Studies of Chronic Active Epstein-Barr Disease nanRECRUITING
Development of a Machine Learning Model for Nasopharyngeal Carcinoma Screening Based on Tongue Imaging nanUNKNOWN
tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella) nanRECRUITING
Xijiang Project Screening Cohort for NPC nanACTIVE_NOT_RECRUITING
Genetic Studies of X-linked Lymphoproliferative Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a EBNA1BP2 binder may also engage these)

ProteinNameSimilarity
Q9D903 0.999 Q9D903 →
Q9I8J6 0.999 Q9I8J6 →
Q9V9Z9 0.993 Q9V9Z9 →
Q09958 0.989 Q09958 →
O13802 0.988 O13802 →
B5VM59 0.987 B5VM59 →
A6ZZL7 0.987 A6ZZL7 →
B6K8A0 0.987 B6K8A0 →
P36049 0.987 P36049 →
Q55C50 0.986 Q55C50 →
Q9VWD4 0.986 Q9VWD4 →
D5GA77 0.986 D5GA77 →
Q75A47 0.986 Q75A47 →
Q6FJP1 0.986 Q6FJP1 →
Q09462 0.986 Q09462 →
Q96EU6 0.986 Q96EU6 →
Q9W3C0 0.986 Q9W3C0 →
A6QNR1 0.985 A6QNR1 →
Q751U1 0.985 Q751U1 →
A3LNR4 0.985 A3LNR4 →
Q9U178 0.985 Q9U178 →
Q10106 0.985 Q10106 →
A5DLD1 0.985 A5DLD1 →
Q6CFU2 0.985 Q6CFU2 →
Q9SH88 0.985 Q9SH88 →
O43051 0.984 O43051 →
Q6CT09 0.984 Q6CT09 →
Q9LUJ5 0.984 Q9LUJ5 →
Q3UFY0 0.984 Q3UFY0 →
Q09867 0.984 Q09867 →